Molecular Tissue Profiling in a Clinically Selected Pancreatic Cancer Cohort
The high frequency of targetable alterations in our cohort underscores upfront NGS testing in PDAC. Younger patients, those with a positive family history, and KRAS WT patients should be of particular interest.
Authors
- Jens Christmann (ORCID: https://orcid.org/0000-0002-8625-2991)
- Anke Reinacher‐Schick (ORCID: https://orcid.org/0000-0002-7838-6877)
- Ira Ekmekçiu
- Elena Schlageter
- Stefanie Hegenberg
- A. Tannapfel
- Tobias Germing
Institutions
- St. Josef-Hospital (DE)
- Ruhr University Bochum (DE)
Publication Details
- Journal
- Oncology Research and Treatment
- Published
- 2025-02-07
- DOI
- https://doi.org/10.1159/000543997
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00